CEO Maurits Geerlings told BioWorld Today that Formula Pharmaceuticals Inc. may have found a way around the drawbacks of chimeric antigen receptor (CAR) methods that deploy autologous T cells, thanks to the worldwide exclusive license the firm has gained to an allogeneic, nonviral CAR platform that leverages instead cytokine-induced killer (CIK) cells as immune effectors.